Alpha Diallo
0
All posts from Alpha Diallo
Alpha Diallo in Alpha Diallo,

Weight-loss and a Dent in Type 2 Diabetes

 (Image source: theindychannel)

The biopharmaceutical company VIVUS, Inc. (NASDAQ:VVUS) released a study highlighting that its weight-loss drug Qsymia has some positive effects on type 2 diabetes. According to the study, in addition to weight loss, obese patients who toke the drug over a 2 year period saw a 78.7 percent reductions in the chance of developing symptoms of type 2 diabetes. Those risk factors are mitigated by the drug. Obese is one of the leading factors of type 2 diabetes. The stock is trading above 1 percent on the news.